Scilex Holding Company Total Assets
Scilex Holding Company total assets. Based on the latest financial reports, Scilex Holding Company (SCLX) holds total assets worth $253.56 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Scilex Holding Company for the company's overall valuation and market capitalisation.
Total Assets of Scilex Holding Company (2020–2025)
Total assets of Scilex Holding Company from 2020 to 2025. This chart illustrates how Scilex Holding Company's total assets have evolved over time, based on quarterly financial data. See Scilex Holding Company (SCLX) share price today for real-time trading data and today's change.
Scilex Holding Company - Asset Composition Analysis
Scilex Holding Company Total Assets Breakdown (December 2025)
Scilex Holding Company total assets breakdown as of December 2025. Scilex Holding Company's total assets of $253.56 Million consist of 10.5% current assets and 89.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.4% |
| Accounts Receivable | $15.24 Million | 4.2% |
| Inventory | $4.79 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $59.09 Million | 16.2% |
| Goodwill | $13.48 Million | 3.7% |
Asset Composition Trend (2020–2025)
This chart illustrates how Scilex Holding Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Scilex Holding Company's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scilex Holding Company's current assets represent 10.5% of total assets in 2025, a decrease from 27.5% in 2020.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 5.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, a decrease from 68.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 16.2% of total assets.
Scilex Holding Company Competitors by Total Assets
Key competitors of Scilex Holding Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Scilex Holding Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.11 | 5.33 |
| Quick Ratio | 0.06 | 0.10 | -9.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-476.01 Million | $-272.26 Million | $188.61K |
Scilex Holding Company - Advanced Valuation Insights
This section examines the relationship between Scilex Holding Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.85 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 292.7% |
| Total Assets | $364.98 Million |
| Market Capitalization | $12.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scilex Holding Company's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Scilex Holding Company's assets grew by 292.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Scilex Holding Company (2020–2025)
The table below shows the annual total assets of Scilex Holding Company from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $364.98 Million | +292.65% |
| 2024-12-31 | $92.95 Million | -8.25% |
| 2023-12-31 | $101.31 Million | +17.08% |
| 2022-12-31 | $86.53 Million | +11.03% |
| 2021-12-31 | $77.93 Million | -4.38% |
| 2020-12-31 | $81.50 Million | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more